TerminatedPhase 2

Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

Stopped: inability to achieve recruitment goals at a single center and given the current pandemic conditions

United States17 participantsStarted 2019-03-10

Plain-language summary

Aim 1. To determine the effect of Allopurinol treatment on renal function (glomerular filtration rate, GFR) in pediatric chronic kidney disease (CKD) patients with high uric acid levels (hyperuricemia). Aim 2. Establish whether Allopurinol treatment reduces Nlrp3 inflammasome and renal injury biomarkers.

Who can participate

Age range2 Years – 20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Chronic Kidney Disease stage 1-5 * Hyperuricemic (UA \>= 5.5 mg/dL) Exclusion Criteria: * Contraindication to Allopurinol * Elevated baseline liver function tests * Receiving acute or chronic dialysis * Primary metabolic disorder * Sickle cell disease * Autosomal Dominant Polycystic Kidney Disease * Cystinosis * Bartter or Gitelman Disease * Pregnant or nursing

What they're measuring

eGFR Change

Timeframe: The difference in Cystatin C eGFR between baseline and 6 months will be measured

eGFR Change

Timeframe: The difference in Creatinine eGFR between baseline and 6 months will be measured

Trial details

NCT IDNCT03865407

SponsorVirginia Commonwealth University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-10-07

Results submitted2021-05-04

View on ClinicalTrials.gov More Hyperuricemia trials